These results suggest that serum S100A8/A9 levels may serve as a predictor of tumor responses to specific treatments and subsequent disease progression (i.e., Fig. 1a), rather than reflecting breast cancer stages. This evidence concerns the gene S100A8 and breast carcinoma.